Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053
Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053
复制标题
DOI：
10.1021/acs.molpharmaceut.1c00733
复制
发表时间：
2022-10-03
影响因子：
4.9
通讯作者：
Liu, Jianjun
中科院分区：
文献类型：
--
作者：
Wei, Weijun;Zhang, Di;Liu, Jianjun
多发性骨髓瘤（MM）的非侵入性诊断是一个临床挑战。CD 38是MM的既定生物标志物，并且靶向CD 38的放射性示踪剂的开发可以改善MM的管理。Nb 1053-LLQS）特异性的，成功地用F-18标记。所开发的示踪剂的诊断功效和特异性（即，[F-18]F-Nb 1053）通过免疫正电子发射断层扫描（immuno-PET）成像在播散性MM. 1 S荷瘤模型中进行评价。[F-18] F-Nb 1053具有高放射化学纯度（>98%）和良好的免疫反应性。[F-18] F-Nb 1053免疫PET成功描绘了临床前MM模型中的播散性MM病变。肱骨、股骨和胫骨中的摄取分别为1.42 +/- 0.50%ID/g、1.35 +/- 0.53%ID/g和1.48 +/- 0.67%ID/g（n = 6）。达雷妥尤单抗术前给药后，[F-18] F-Nb 1053的肿瘤摄取降低，表明报告的探针具有优越的上级特异性。这项工作成功地开发了一种新的CD 38特异性探针[F-18] F-Nb 1053，可能在临床转化后优化MM的管理。
Noninvasive diagnosis of multiple myeloma (MM) is a clinical challenge. CD38 is an established biomarker for MM, and the development of CD38-targeted radiotracers may improve the management of MM. By taking the advantages of bioorthogorml click chemistry, a nanobody (i.e., Nb1053-LLQS) specific for ( I was successfully labeled with F-18. The diagnostic efficacy and specificity of the developed tracer (i.e., [F-18]F-Nb 1053) were evaluated by immuno-positron emission tomography (immuno-PET) imaging in disseminated MM.1S-bearing models. [F-18]F-Nb1053 was developed with high radiochemical purity (>98%) and excellent immunoreactivity. [F-18]F-Nb1053 immuno-PET successfully delineated disseminated MM lesions in preclinical MM models. The uptake in the humerus, femur, and tibia was 1.42 +/- 0.50%ID/g, 1.35 +/- 0.53%ID/g, and 1.48 +/- 0.67%ID/g (n = 6), respectively. Tumor uptake of [F-18]F-Nb1053 decreased after daratumumab premedication, indicating the superior specificity of the reported probe. This work successfully developed a novel CD38-specific probe [F-18]F-Nb1053 that may potentially optimize the management of MM upon clinical translation.